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Summary.-Optimized methods for extraction and enzyme assay in crude tissue
preparations were used to determine the amounts of terminal deoxinucleotidyl
transferase (TdT) in malignant lymphomas. The TdT concentration was increased
only in lymphoblastic lymphomas (LL) and was as high in these tumours as in the
white blood cells from untreated patients with acute lymphoblastic leukaemia
(ALL). The enzymes extracted from such lymphomas and from the leukaemic lym-
phoblasts had the same properties. Moreover, forms of TdT with low and high mol.
wt were found in the LL tumours, similar to other reports ofTdT-positive leukaemias.
The overall study points at some basic biochemical identity of certain lympho-
blastic malignancies, irrespective of whether the transformed cells are in solid
tumours or are disseminated in the blood.
THE ENZYME TERMINAL deoxynucleo-
tidyl transferase (TdT) catalyzes tle
random condensation of deoxynucleotidyl
residues on the 3'-OH termini of single-
stranded DNA and of oligodeoxynucleo-
tides (Bollum et al., 1964; Chang & Bollum,
1971 ; Kato et al., 1]967; Yoneda & Bollum,
1965). TdT has a restricted distribution in
nature, and is abundant onlyinthethymus
of higher animals (Bollum, 1978), but it
can be detected also in the marrow (Barr
et al., 1976; Gregoire et al., 1977; Kung et
et., 1975; Pazmino et al., 1977) and transi-
ently in the spleen (Gregoire et al., 1979).
The enzyme is expressed in undifferenti-
ated clones of migrating lynmphoid cells
that will finally evolve to T lymphocytes
in the thymus (Bollum, 1979; Gregoire et
al., 1979; Silverstone et al., 1976).
A general interest in TdT arose in 1973
after the reported presence of the enzyme
in the neoplastic cells of acuite lymphatic
leukaemia (ALL) (McCaffrey et al., 1973;
Srivastava & Minowada, 1973). Subse-
quently, TdT was found in the white
blood cells from individuals with chronic
myelogenous leukaemia (CML) during the
blastic phase (Bhattacharyya, 1975; Sarin
& Gallo, 1974; Srivastava et al., 1977) and
in the blast cells from patients with acute
undifferentiated leukaemia (AUL) (Kung
et al., 1978; Marcus et al., 1976). The data
gained to date (Coleman et al., 1976, 1978;
Greenwood et al., 1977; Hutton et al.,
1979; Kung et al., 1978; McCaffrey et al.,
1975; Sarin et al., 1976) show that high
levels of TdT are encountered in the
immature cells from: most cases of ALL;
25-50% of CML in blast crisis; and a
number of the so-called AUL. For these
leukaemias, TdT is also a useful marker
for the prediction of the response to
therapy, since the cells with high TdT
activity are often sensitive to cortisone
(Kung et al., 1975; Sobhy & Chirpich,
1975).
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Solid lymphoid tumours have not been
as extensively investigated with regard to
TdT as leukaemia. Apparently, only the
rare lymphoblastic lymphomas (LL) have
raised levels of TdT (Donlon et al., 1977;
Habeshaw et al., 1979; Kung et al., 1978).
This paper complements the existing
reports on the distribution of TdT in
different lymphomas. It confirms that the
enzyme is functionally expressed in the
LL tissue and it shows that the intra-
cellular concentration of TdT in these
tumours can be as high as in the blasts in
peripheral blood from ALL patients. We
have also found either small or large mol.-
wt forms of TdT in the LL tumours,
similar to the enzymes of low (Coleman et
al., 1974b; Marcus et al., 1976; Sarin et al.,
1976) andhighmol. wts (Deibel & Coleinan,
1979) that had been described in TdT+
leukaemias.
MATERIALS AND METHODS
Patients.-Neoplastic lymphoidtissues from
31 males and 18 females of ages ranging from
5-77, as well as non-neoplastic lymph nodes
from 8 patients, were analysed. The lymph-
oma samples were from lymph nodes in 47
cases and from mediastinal masses in 2. They
were obtained directly from the operating
room after surgery, immediately frozen and
stored at -70°C until use. For the sake of
comparison, white mononucleated cells of
peripheral blood from 3 patients with TdT+
leukaemias were also included in the study.
Solid lymphoid tumours were classified
histologically as proposed by Rappaport
(1968) with the additional criteria introduced
by Nathwani et al. (1976) for the definition
ofLL.
Chemicals and reagents.-Radioactive de-
oxynucleotides were purchased from Radio-
chemical Centre, Amersham. Unlabelled de-
oxynucleotides were from PL Biochemicals.
Poly(dA)55 was prepared enzymatically in our
laboratory via the end addition reaction
catalysed by purified bovine TdT in the
presence of an oligo(dA)6 initiator and
dATP-Mg substrates (Kato et al., 1967).
Tissue and cell extracts.-All procedures
were carried out at 20C. The frozen tissues
were thawed, rinsed with saline, minced finely
and suspended in 5 volumes of 0-25M potas-
sium phosphate (pH 7.2). The mononucleated
cells isolated from heparinized blood of
leukaemia patients by centrifugation on
Ficoll gradients (Boyum, 1968) were dis-
persed in the same phosphate buffer at a con-
centration of 2 x 108 cells/ml. The tissue and
cell samples were disrupted in a Dounce
homogenizer and the homogenates were spun
at 100,000 g for 60 min. The supernatants
obtained after centrifugation were considered
as the crude extracts. Proteins were measured
by the method of Bradford (1976), using
human gamma-globulin as standard.
Assays of TdT.-The activity of human
TdT was determined by measuring the in-
duced polymerization of dGTP on an acid-
insoluble (dA)n initiator as suggested by the
group of Bollum for optimizing the enzyme
assay in crude cell extracts (Chang, 1971;
Chang & Bollum, 1971; Coleman et al., 1974a,
1976). Care was taken to choose reaction con-
ditions ensuring maximal rates of catalysis.
The composition of the standard assay was
guided by the kinetic data obtained experi-
mentally with an active lymphoma extract.
and is presented under Results. The method
finally adopted uses Mn++ instead of Mg++ as
metal cofactor and is similar to that proposed
by Coleman (1977a, b) for studying human
leukaemias. One unit of TdT is the amount
polymerizing 1 nmol of nucleotide material
in 1 h. TdT activity is expressed in terms of
units/0.1 g of tissue, a mass estimated as
equivalent to 108 cells (Donlon et al., 1977).
The TdT activity from calf thymus, puri-
fied according to the method of Yoneda &
Bollum (1965), was assayed for comparison
with the human TdT in our standard incuba-
tion mixture. Parallel assays were run also
with 8mM Mg++ as the divalent metal co-
factor.
Ultracentrifugation analysis on sucrose
gradients.-Sedimentation analysis of TdT
activity in the tissue and cell extracts was
carried out by centrifugation on sucrose
gradients according to Martin & Ames (1961).
Linear gradients from 5-20%/ sucrose in
50mM Tris-HCI (pH 8.0), 500mM NaCl, 1mM
EDTA were prepared in the cellulose nitrate
tubes of the SW 50.1 rotor of a Beckman
L8-70 ultracentrifuge, and were overlaid with
0-2 ml aliquots of crude extracts. The
gradients were spun for 18 h at 40,000 rev/
min at 2°C. After centrifugation, serial frac-
tions were collected from the bottom of the
tubes and analysed for TdT activity. Bovine
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FIG. 1.-Requirements for the assay of TdT
in crude extracts from human lymphoma:
saturation curves for primer, substrate and
metal cofactors. The assay mixtures con-
tained an active extract from the Lm4
lymphoma, the standard reactants and the
indicated amounts of poly(dA)55 primer,
dGTP substrate and divalent metal cofac-
tors. The data refer to initial polymeri-
zation rates expressed as deoxynucleo-
tides incorporated into the acid-insoluble
primer in 1 h at 37°C. The enzyme aliquots
per ml of the final incubation mixtures
corresponded to the TdT extracted from
0 03 g of tumour tissue.
serum albumin and chymotrypsinogen were
used as markers for the determination of the
sedimentation coefficient, S.
RESULTS
Conditions ofthe assay
The catalytic requirements of human
TdT were preliminarily determined using
an active extract from the lymphoblastic
lymphoma Lm4 as a source ofthe enzyme.
The relevant data are presented in Fig. 1.
The TdT activity was almost saturated
by 7.5,uM poly(dA)55 as 3'-OH termini
(panel a), and this was taken into account
for defining 10utMpoly(dA)55 as the optimal
concentration of initiator in the standard
assay.
The rates of TdT reaction increased
almost linearly on raising the concentra-
tion of dGTP substrate up to 0.2 mM,
reached a maximum in the range of 0-2 to
1mM dGTP, and declined, because of
inhibition, at higher levels (panel b).
The curves obtained for the saturation
of TdT with Mg++ and Mn++ as metal
cofactors are shown in panels c and d of
Fig. 1, respectively. In contrast to the
bovine TdT, the human enzyme clearly
preferred Mn++ to Mg++ for active cata-
lysis with a (dA)n initiator as first noted
by Bhattacharyya (1975). In fact the Lm4
TdT became practically saturated at
0 2-1 0mM Mn++, i.e. in a range one order
of magnitude lower than the one needed
by Mg++ for optimal enzymatic activity.
Moreover, the maximal reaction rates
obtained in the presence of Mn++ were
almost 3-fold higher than those observed
with saturating Mg++ concentrations. This
led us to choose 0.5mM Mn++ as the metal
cofactor in the standard assay.
The adopted mixture for the standard
assay contained: 0.2M K-cacodylate (pH
7.0), 0 5mM MnCl2, 0 5mM [3H]dGTP (104
ct/min/nmol), 1lOpM poly(dA)55 as 3'-OH
and 20 pl ofcrude extract in a final volume
of 100 ,ul. The reaction was run at 37°C for
up to 1 h, the time kinetics always being
linear for 15 min and for up to 60 min in
many instances. Aliquots (20 pl) of the
assay mixture were drawn at various inter-
vals oftime, spotted on discs ofglass-fibre
paper (Whatman GF/C) and processed for
the determination of radioactivity in the
acid-insoluble material, as previously de-
scribed (Bekkering-Kuylaars & Campag-
nari, 1972).
Distribution of TdT activity in lymphontas
Table I shows the various types of
lymphoid tissues under study, and lists
histological diagnosis, number of cases and
the TdT concentrations. Most of the
patients didnot receive antiblastic therapy
before the biopsy. The non-neoplastic
lymph nodes taken as controls had a mean
TdT content of 1-3 u/0-1 g of tissue, with
values ranging from 0-5 to 2-7 times the
mean.
The only group of lymphomas display-
ing high TdT activity was that of the
314TdT IN HUMAN LYMPHOMAS
TABLE L.-Distribution ofTdT in lymphoid cells
Positive cells
Lymphoblastic lymphoma (LL)
Untreated
Under drug treatment
Acute lymphoblastic leukemia (ALL)
Chronic myelogenous leukemia, blast crisis (Cl
Negative cells
Hodgkin's disease
Nodular sclerosis
Mixed cellularity
Lymphocytic predominance
Non-Hodgkin's lymphoma
Diffuse hystiocytic
Diffuse lymphocytic, well differentiated
Diffuse lymphocytic, poorly differentiated
Diffuse mixed
Nodular lymphocytic, poorly differentiated
Burkitt's
Non-neoplastic lymph nodes
lymphoblastic type, LL. The neoplastic
cells of the 4 untreated patients with this
disease had concentrations of TdT that
were about two orders of magnitude
higher than the values found in non-
neoplastic lymph nodes and in other
lymphomas, and 1-5 to 3-fold larger than
those in the leucocytes of the 2 ALL
patients. The very large amounts of TdT
found in the LL tumours at diagnosis are
similar to those found by others with the
same type of enzyme assay in mono-
nucleated cells from blood and marrow of
patients with either untreated TdT+
leukaemias (Coleman, 1977a; Coleman et
al., 1978) or leukaemic dissemination of
LL (Hutton et al., 1979).
A slightly raised level ofTdT was found
in the neoplastic tissue of an individual
affected by LL and successfully treated
with cortisone and cytostatic drugs. The
TdT concentration in this tumour was far
below the ones detected in the untreated
LLs. Obviously, the expression of TdT in
LL cells might depend upon the course of
the disease in response to drug and hor-
mone treatments. Within this context, the
monitoring of the TdT concentration in
No. of
cases
4
1
2
15
2
2
12
9
3
3
3
2
8
TdT/0.1 g of tissue or 108
cells
A~~~
Means or
single
values Ranges
455
24
205; 225
1414
0-88
0-75-1-02
0-20; 3-60
1-10
0-61; 0-65
1-12
1-73
0-94
1-30; 2-40
1-29
304-650
0-29-2-01
0-23-1-89
0-85-133
1-21-2-26
0-53-1-20
0 67-3 59
LL is a useful clinical index for both the
development of the tumour and its re-
sponse to therapy as already noted by
others in the leukaemias (Coleman et al.,
1976; Marks et al., 1978).
The TdT activities measured in the
solid lymphoid tissues were in general 10
times larger than those found by previous
investigators (Donlon et al., 1977; Habes-
haw et al., 1979; Kung et al., 1978). This
refers to the LL tumours and to the other
lymphomas with apparently normal en-
zyme content, but it applies also to non-
neoplastic lymph nodes. The discrepancy
must be related to methodological differ-
ences in the determination of the TdT
activity in crude tissue extracts, and it
will be commented upon under Dis-
cussion.
Comparative study ofthe TdTactivitiesfrom
lymphomas and leukaemias relative to
purified bovine TdT
The properties of the TdT extracted
from LL tissue and from ALL cells were
compared. The enzymes from the two
sources yielded similar responses to the
changes of the reactant concentrations in
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the assay. In fact, both TdT activities
showed the same catalytic requirements
and were saturated by the same distinctive
concentrations of metal cofactors, dGTP
and poly(dA)55. When dGTP was substi-
tuted by other deoxynucleoside triphos-
phates in the reaction mixture, the TdTs
from both LL and ALL gave again the
same response (Table II).
TABLE II.-Differential incorporation of
various nucleotides intopoly(dA)55primer
by bovine and human TdT
Nucleo-
tide
dGTP
dATP
dCTP
dTTP
dUTP
Bovine
thymus TdT
A
Mg++ Mn++
123 100
40 22
18 25
71 92
18 71
Human TdT
Lm22 Lk5
lymphoma leukaemia
Mn++ Mn++
100 100
7 9
30
21
14
42
27
15
The reactions were carried out as described for the
routine TdT assay with either the standard system
of 0-5mM dGTP as a substrate and 0-5mM MnCl2
as a metal cofactor, or the indicated substitutions
of 0 5mM dNTP nucleotide and 8mM MgCl2. The
enzyme aliquots in the O lml assay mixtures were:
30 u of purified bovine TdT and the amounts of
human TdT extracted from either 3-3 mg of tumour
tissue or 4 x 105 mononuclear cells of leukaemic
blood. Incubation was at 37°C for 10 min. The data
are expressed as relative percentages of the poly-
merization value obtained with the standard dGTP-
Mn combination.
However, the polymerization pattern
obtained with the various nucleotides was
different from that displayed by the puri-
fied TdT from calf thymus, which was
tested in the presence of either Mn++ or
Mg++. In this regard, the most striking
difference was the much greater ability of
the bovine enzyme to polymerize dUTP
and dTTP substrates under our standard
assay conditions (Table II).
Sedimentationprqfiles of human TdT
The sedimentation analyses of the TdT
recovered from cells of the two LLs and
one ALL are presented in Fig. 2. The TdT
activities from the Lm4 lymphoma and
the Lk5 leukaemia yielded similar pro-
files after centrifugation on sucrose
5 10 15 20
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FIG. 2.-Sedimentation profiles of TdT
extracted from 2 lymphoblastic lympho-
mas, and from the mononuclear blood cells
of a patient with acute lymphoblastic leu-
kaemia. Extracts corresponding to 0 03 g
of tissue for the Lm22 and Lm4 lym-
phomas and to 3 x 107 cells for the Lk5
leukaemia were sedimented by centrifuga-
tion into sucrose gradients as described in
Materials and Methods. The fractions were
collected from the bottom of the tubes and
20Fd aliquots were analysed for TdT
activity. The assays were run at 37°C for
30 min in 01 ml reaction mixture. The
arrow indicates the position of purified calf
thymus TdT sedimented in comparative
ultracentrifugations.
gradients, and their estimated sedimen-
tation coefficient of 3*45 and 3*70 S
approached the 3*65 S measurement
reported for the bovine thymus TdT
(Chang & Bollum, 1971). These data agree
with the results by otherinvestigators who
found identical S values for the TdT
enzymes from calf thymus and from the
white blood cells from cases of acute
myelomonocytic leukaemia (Coleman etal.,
1974b), of CML in blast crisis (Marcus et
al., 1976) and ofALL (Sarin et al., 1976).
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On the other hand, the TdT activity of
the extract from the Lm22 lymphoma
(Fig. 2) sedimented faster than the Lm4
and Lk5 enzymes, and had a distinctly
higher S value of 4-2. In this respect we
should recall that TdT species with un-
expectedly high mol. wt of about 60,000
have beennotedin theneoplastic cells from
two leukaemicpatients (Diebel & Coleman,
1979) and from cultured human lympho-
blastoid cells (Bollum & Brown, 1979).
As a matter of fact, our value of 4-2 S for
the Lm22 would correspond to an apparent
molecular size close to that estimated for
the larger TdT enzymes.
DISCUSSION
The methods for the determination of
TdT in extracts from human leukaemic
cells have been extensively discussed by
Coleman (1977a, b). The recommended
techniques involve the homogenization of
the sample in buffers with relatively high
salt concentrations and an enzymatic
assay measuring the polymerization of
dGTP on acid-insoluble (dA)n primers in
the presence of Mn++.
We searched preliminarily for the best
conditions to extract and to assay the
TdT fronm normal and neoplastic lymph
nodes. The standardized procedures per-
mitted the detection of TdT levels that
were all shifted to higher scale values than
those found in solid lymphoid tumours
with non-optimized assays by other in-
vestigators (Donlan et al., 1977; Habeshaw
et al., 1979; Kung et al., 1978).
Except for the quantitative scale differ-
ence of all the measurements, the TdT
distribution we have noted in lymphoid
tissues agrees with the previous investiga-
tions, showing abnormally high enzymatic
activity in extracts from tumours that
were classified as LL (Donlon et al., 1]977;
Habeshaw et al., 1979; Kung et al., 1978).
As a matter offact, the TdT enzymes from
LL and from ALL showed similar intra-
cellular increments over the average con-
tent oflymphoid tissues, and had the same
catalytic properties.
The recent reports that human leuk-
aemic cells can be endowed with TdT
species with apparently the same molecu-
lar size as the enzyme isolated from calf
thymus (Coleman et al., 1974b; Marcus et
al., 1976; Sarin et al., 1976) or a higher
mol. wt (Bollum & Brown, 1979; Deibel &
Coleman, 1979) were matched by the
results of our sedimentation analyses of
the active extracts from LL tissues. Like
the analogous leukaemias, these lympho-
blastic tumours might consist of cell
clones with functional expression of one or
other form of TdT. Taken altogether the
above observations seem to point to some
basic biochemical similarity of the acute
lymphoblastic malignancies, quite inde-
pendent of the retention of the trans-
formed cells in solid tumours or on their
release into the blood.
TdT was first discovered in calf thymus
and found to consist of a small protein
with two distinct peptide chains (Chang &
Bollum, 1971). Initially regarded as an
enzyme unique to thymus and of cyto-
plasmic origin (Bollum, 1978; Yoneda &
Bollum, 1965), the TdT has been subse-
quently detected in marrow (Barr et al.,
1976; Gregoire et al., 1977; Kung et al.,
1975; Pazmino et al., 1977) and also
in other organs, during embryogenesis
(Bollum, 1979; Gregoire et al., 1979).
Refined immunofluorescence methods
showed that, in adult animals, TdT is
localized to the nuclei of marrow cells and
of large cortical thymocytes and to the
cytoplasm ofthe small cortical thymocytes
(Gregoire et al., 1979). Apparently, the
high-mol.-wt human TdT isolated from
lymphoblastoid cells in culture (Bollum &
Brown, 1979) and from leukaemic cells
(Deibel & Coleman, 1977) is devoid of
subunit structure and consists of a single
polypeptide.
Bollum correlated the distinct molecular
species of TdT with their intracellular
location and function in thymus and non-
thymic tissues (Bollum & Brown, 1979).
He suggested that the large TdT poly-
peptide in the nucleus of prothymocytes
might be the functionally active enzyme
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which undergoes a post-translational
cleavage ofits peptide chain during differ-
entiation in the thymus. The small TdT
found in the cytoplasm of cortical thymo-
cytes would result from the processing of
the original gene product. This hypothesis
muist await further experimental support,
since the intracellular product of TdT has
not been identified as yet, and the func-
tions of the enzyme in the nucleus and in
the cytoplasm of the lymphopoietic cells
remain to be elucidated. Moreover, limited
proteolysis is often a step in the matura-
tion of proteins, and the peptide-chain
cleavage of TdT in the thymus might not
be a simple degradative operation. Any-
way, the distinct forms ofTdT in lymphoid
neoplasias might reasonably be viewed
as specific markers for populations of
immature lymphocytes that underwent
malignant transformation at different
stages of maturation.
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